Physician profile
Matthew Michael Schellenberg
NPI 1386855021
$2,328.35
in general payments reported to CMS, 2019-2025
36 companies · $15.45 in 2025
The $15.45 reported for 2025 was less than what a typical Hospice and Palliative Medicine (Family Medicine) provider received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $815 · 2021: $33.39 · 2025: $15.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $228.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $217.02 | 2019-2020 | |
| Lilly USA, LLC | $195.46 | 2019-2020 | |
| Amarin Pharma, INC. | $150.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.46 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $110.35 | 2019-2020 | |
| Astellas Pharma US INC | $107.78 | 2019-2020 | |
| Pfizer INC. | $106.20 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $102.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $101.42 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $95.39 | 2019-2020 | |
| Novo Nordisk INC | $91.12 | 2019-2020 | |
| Allergan, INC. | $90.98 | 2019-2020 | |
| Boston Scientific Corporation | $86.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $78.51 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $34.73 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $32.44 | 2019-2020 | |
| Insulet Corporation | $31.64 | 2020 | |
| Arbor Pharmaceuticals, INC. | $31.57 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $30.57 | 2019-2020 | |
| Nevro Corp. | $27.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.05 | 2019-2020 | |
| Mylan Specialty L.P. | $22.99 | 2019 | |
| Abbott Laboratories | $20.89 | 2020 | |
| Upsher-Smith Laboratories LLC | $18.25 | 2020 | |
| Gilead Sciences, INC. | $16.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.75 | 2019 | |
| Antares Pharma, INC. | $16.14 | 2019 | |
| Mannkind Corporation | $15.70 | 2020 | |
| Biogen, INC. | $15.55 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.16 | 2020 | |
| Circassia INC. | $14.09 | 2019 | |
| Eisai INC. | $13.20 | 2020 | |
| Sanofi Pasteur INC. | $12.70 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Schellenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.